EXPERIMENTAL NEPHROTOXICITY, HEPATOTOXICITY AND PHARMACOKINETICS OF CYCLOSPORINE-G VERSUS CYCLOSPORINE-A

被引:31
作者
BURDMANN, EA
ANDOH, TF
ROSEN, S
LINDSLEY, J
MUNAR, MY
ELZINGA, LW
BENNETT, WM
机构
[1] OREGON HLTH SCI UNIV,DIV NEPHROL HYPERTENS & CLIN PHARMACOL,PORTLAND,OR
[2] HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115
[3] BETH ISRAEL HOSP,BOSTON,MA 02215
基金
巴西圣保罗研究基金会;
关键词
D O I
10.1038/ki.1994.92
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cyclosporin G (CsG) is an analogue of cyclosporin A (CsA) with strong immunosuppressive activity. We compared these two drugs in a rat model in which salt depletion promotes irreversible renal interstitial fibrosis with renal dysfunction in animals given CsA for three weeks. When both drugs were given in the same dosage on a weight basis (15 mg/kg/day, subcutaneously), CsA blood levels were higher than CsG (3305 vs. 1824 ng/ml, P < 0.001). This could be explained by a higher CsG clearance (6.4 vs. 4.3 ml/min/kg in CsA, P < 0.0001) resulting in smaller CsG area under the curve. There was also lower renal and hepatic CsG tissue concentrations. CsA induced a dramatic decrease in GFR, 0.14 in CsA versus 0.67 ml/min/100 g in control, P < 0.001, and increased urinary excretion of N-acetyl beta-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in control rats, P < 0.001. CsG-treated and control rats had similar GFR and urinary NAG. When CsA dosage was decreased to 7.5 mg/kg blood levels were similar to those found with CsG 15 mg/kg. CsA at this dose caused a reduced GFR (0.29 ml/min/100 g) and an increased urinary NAG (20 IU/gCr) (P < 0.01 vs, control for both). Both dosages of CsA induced considerable cortical and medullary injury (interstitial fibrosis and tubular atrophy), more severe than the histological damage found in CsG-treated rats. Neither drug promoted significant changes in liver function or histology. These results demonstrate that CsG caused less renal interstitial fibrosis and functional changes than CsA when the drugs were given at the same dosage or when similar blood levels of each drug were achieved.
引用
收藏
页码:684 / 691
页数:8
相关论文
共 44 条
[1]  
ADAMS M, 1992, AM SOC TRANSPLANT PH, V11, P71
[2]   MODULATION OF METABOLISM IN HEPG2 CELLS UPON TREATMENT WITH CYCLOSPORINE-A AND NVA2-CYCLOSPORINE [J].
BACKMAN, L ;
APPELKVIST, EL ;
SUNDBERG, A ;
TECLEBRHAN, H ;
BRUNK, U .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1991, 54 (03) :242-254
[3]   EFFECTS OF A 2-MONTH TREATMENT WITH LOW ORAL DOSES OF CYCLOSPORINE ON RENAL-FUNCTION [J].
BALLETTA, M ;
LIBETTA, C ;
FUIANO, G ;
DELFINO, M ;
BRUNETTI, B ;
UNGARO, B ;
CONTE, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1991, 6 (05) :324-329
[4]  
BECKER GM, 1987, RES COMMUN CHEM PATH, V56, P277
[5]  
BURDMANN EA, IN PRESS NEPRHOL DIA
[6]  
COLLIER SJ, 1986, LANCET, V1, P216
[7]   THE ISOLATION, STRUCTURAL CHARACTERIZATION, AND IMMUNOSUPPRESSIVE ACTIVITY OF CYCLOSPORINE-G (NVA2-CYCLOSPORINE) METABOLITES [J].
COPELAND, KR ;
YATSCOFF, RW .
THERAPEUTIC DRUG MONITORING, 1991, 13 (04) :281-288
[8]  
DONNELLY JG, 1993, CLIN CHEM, V39, P122
[9]  
DSOUZA MJ, 1988, DRUG METAB DISPOS, V16, P895
[10]  
DUNCAN JI, 1986, TRANSPLANTATION, V42, P395